Accelerate the Selection, Identification, & Validation of Personalized & Shared Neoantigens to Create Meaningful T Cell Responses

The 6th Annual Neoantigen Based Therapies Summit returns as your comprehensive guide to transforming the clinical development of cell and vaccine based neoantigen therapies.

Across 3 days of carefully curated sessions, you can look forward to gathering with over 100 of the leading C-Level executives and KOLs in the neoantigen field from the likes of BioNTech, Gritstone, Advaxis, Genocea, Treos Bio to explore the potential of shared neoantigens vs. personalized neoantigens and optimizing the selection and identification of the best and most immunogenic neoantigens for enhanced anti-tumor responses.

Promising novel clinical data, interactive discussion, and engaging networking opportunities, you will leave the Neoantigen Based Therapies Summit equipped with new collaborations across pharma, biotech and academia, and advanced knowledge on how to supercharge vaccine and cell immunotherapies for solid tumors and beyond.

You can’t afford to miss the Neoantigen Based Therapies Summit as we bring you an abundance of new data, innovative insights and valuable lessons learned on how to drive meaningful clinical responses.

A Snapshot of Companies That Attended in 2020

Attending companies banner

2021 Expert Speakers Include

Hear What Our Attendees Say

"Great opportunity to learn how to develop and accelerate neoantigen related products not only from speakers but also participants and partners."

BrightPath Biotherapeutics

"The Neoantigen Summit is the focal point for updates in the cancer neoantigen vaccine field and should be attended by everybody with a keen interest in the field."


Proud To Partner With

Industry Development Partner:
Expertise Partners:
Program Partners:
Gyros logo
GenScript Logo_1080x1080